Skip to main content
. 2021 Oct 8;11:679287. doi: 10.3389/fonc.2021.679287

Figure 3.

Figure 3

Patients with a pretherapeutic SUVmax of nodal metastasis ≥ 10.5 (A) and an NLR ≥ 3.75 (B) are at risk of worse disease-specific survival.